Evidence map›Paper›PMID 40178648›Full record

ArticleJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2025

Dapagliflozin Ameliorate Type-2 Diabetes Associated Neuropathy via Regulation of IGF-1R Signaling.

Prabhsimran Kaur, Tashvinder Singh, Laxmipriya Jena, Tanya Gupta, Manjit Kaur Rana, Sandeep Singh, Randhir Singh, Puneet Kumar, Anjana Munshi

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Prabhsimran KaurDepartment of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, 151401, India.
Tashvinder SinghDepartment of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, 151401, India.
Laxmipriya JenaDepartment of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, 151401, India.
Tanya GuptaDepartment of Pharmacology, Central University of Punjab, Bathinda, 151401, India.
Manjit Kaur RanaDepartment of Pathology, All India Institute of Medical Sciences, Bathinda, 151001, India.
Sandeep SinghDepartment of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, 151401, India.
Randhir SinghDepartment of Pharmacology, Central University of Punjab, Bathinda, 151401, India.
Puneet KumarDepartment of Pharmacology, Central University of Punjab, Bathinda, 151401, India.
Anjana MunshiDepartment of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, 151401, India. anjana.munshi@cup.edu.in.ORCID http://orcid.org/0000-0002-7657-8592

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dapagliflozin, an approved SGLT2 inhibitor, has been shown to have extra-glycemic effects like cardio-reno protection. However, the neuroprotective effects of SGLT2 inhibitors against diabetic neuropathy (DN) have not been explored. The current study aimed to determine the neuroprotective potential of Dapagliflozin against STZ-NAD-induced DN in Wistar rats via IGF-1 signaling. DN was induced by STZ-NAD in male Wistar rats. After 60 days of induction, behavioural tests were conducted to access DN, and treatment with Dapagliflozin (0.75 mg/kg & 1.50 mg/kg) was initiated for 30 days. At the end of the study, the brain and sciatic nerve were isolated and expression analysis of IGF-1R signaling molecules was carried out using western blotting, qRTPCR, and immunohistochemistry. Structural changes in the brain and sciatic nerve were ascertained by histopathology. The results showed that treatment with Dapagliflozin improved behavioural parameters in STZ-NAD-induced DN rats. The decreased expression levels of IGF1R signaling pathway molecules and increased expression of p-AKT were found to increase and decrease in the brain and sciatic nerve, respectively after the treatment. Histological studies demonstrated the restoration of normal architecture of the brain and sciatic nerve after treatment with dapagliflozin. The altered expression of IGF-1R signaling molecules established the neuroprotective potential of dapagliflozin against DN.

Indexed as

Benzhydryl CompoundsDiabetes Mellitus, Type 2Diabetic NeuropathiesGlucosidesReceptor, IGF Type 1Sodium-Glucose Transporter 2 InhibitorsAnimalsDiabetes Mellitus, ExperimentalMaleRatsRats, WistarSignal TransductionBenzhydryl CompoundsdapagliflozinGlucosidesIgf1r protein, ratReceptor, IGF Type 1Sodium-Glucose Transporter 2 InhibitorsDapagliflozinDiabetic NeuropathyIGF1R signalingNeuropathy painSGLT2 inhibitors

Identifiers

PMID40178648

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.